Contraline Raises $92.5M in Series B Funding

The round also saw participation from new and existing investors. Iris van Alderwerelt van Rosenburgh, PhD., from BVF Partners L.P., will join Contraline’s Board of Directors.

The company plans to use the funding to advance the late-stage development of NES/T Gel, an investigational hormonal male contraceptive designed to provide a reversible birth control option.

NES/T Gel is an investigational hormonal male contraceptive with the potential to be a first-of-its-kind product. The once-daily topical gel combines segesterone acetate (Nestorone®) and testosterone to reduce sperm production while maintaining normal testosterone levels.

The product recently completed a global Phase 2b clinical trial involving 462 couples and showed positive results for effectiveness, safety, reversibility, and user acceptance. The company expects to begin Phase 3 clinical trials in 2027.

At the same time, Contraline is developing additional male contraceptive options, including ADAM™, an investigational non-hormonal contraceptive designed to provide long-lasting and reversible birth control. The product is currently being evaluated in clinical studies.

“Male contraception represents one of the largest unmet needs in reproductive health,” said Kevin Eisenfrats, co-founder and CEO of Contraline. “Our mission at Contraline is to create new contraceptive options that expand reproductive choice for men and couples. Survey data suggest that more than 40 million men in the United States would consider using a novel male contraceptive, highlighting both the scale of the market opportunity, and the potential impact our products could have on men’s and women’s health.”

“This financing enables Contraline to advance NES/T through Phase 3 development and positions the program to become the first approved pharmacologic contraceptive for men potentially. We believe this is a meaningful step towards expanding contraceptive options for men and couples worldwide,” said Iris van Alderwerelt van Rosenburgh, PhD. of BVF Partners L.P.

Read More:Novellia Raises $18M in Series A Funding Led by Spark Capital

“Male contraception has long been an overlooked area,” said Laura Stoppel, Partner at RA Capital Management. Contraline is helping redefine what reproductive choice can look like by giving men a more active role in family planning, and expanding options for couples whose existing contraceptives may not well serve them. We’re excited to be a part of this new chapter in reproductive health.”

About Contraline

Founded in 2015 by Kevin Eisenfrats, Contraline is a clinical-stage biotechnology company focused on male reproductive health. The company is developing both hormonal and non-hormonal male contraceptive technologies to provide more family planning options for men and couples around the world.

Read More:Plot Raises $10M in Seed Funding Led by XYZ Venture Capital